Background:
Subclinical cardiovascular disease (CVD) remains increased among persons with HIV(PWH). We have shown unique renin-angiotensin-aldosterone system (RAAS) physiology among PWH such that increased RAAS activation is associated with non-traditional CVD risk factors, including visceral adiposity, insulin resistance, inflammation, and altered natriuretic peptides. We sought to understand how RAAS blockade may improve CVD in HIV.
Methods:
40 PWH without known CVD on stable ART with HIV viral load< 100 c/mL were randomized to eplerenone 50mg (n=20) vs. placebo (n=20) BID in a 12-month double-blinded, placebo-controlled trial. Myocardial indices were assessed by coronary PET and cardiac MRI. Change was determined by T-test or Wilcoxon Rank Sums Test depending on normality of distribution.
Results:
Treatment groups (eplerenone vs. placebo) were similar for age (53±7 vs. 56±6 yrs), male sex (75 vs. 75%), white race (55 vs. 55%), HIV duration (20±8 vs. 21±7 yrs), and CD4+ count (814[617,916] vs. 740[545,1122] cells/mL). Change in coronary flow reserve (CFR) on coronary PET was not significantly different(0.01±0.64 vs. -0.07±0.48, P=NS, eplerenone vs. placebo). In ITT analyses accounting for missing data, a higher proportion in the eplerenone vs. placebo group had improvements in CFR(75 vs. 40%, P=.02). In a subset analysis among those with impaired baseline CFR, eplerenone significantly improved CFR vs. placebo (0.28±0.27 vs. -0.05±0.36, P=.04). Eplerenone improved myocardial parameters on cardiac MRI including left ventricular end diastolic volume (-13±28 vs. 10±26mL, P=.03), global circumferential strain (-1[-3,1] vs. 2[0,4]s-1, P=.03), and stress myocardial blood flow (0.09±0.56 vs. -0.53±0.68 mL/min/g, P=.03). There was an increase in CD4+ count (127[-38,286] vs. -6[-168,53]cells/mL, P=.02) and a trend towards reductions in hsIL-6 (-0.8[-1.8, 0.4] vs. 0.2[-0.5, 2.2]pg/mL, P=.07) and hs-cTnT (0[-0.1, 0] vs. 0[0, 0.7]ng/L, P=.09) in the eplerenone vs. placebo-treated groups. Eplerenone was well-tolerated among PWH and lowered systolic blood pressure (-16±14 vs. -4±14 mmHg, P=.03) compared to placebo.
Conclusions:
RAAS blockade with eplerenone improved key myocardial perfusion and diastolic dysfunction parameters among PWH. In addition, CFR improved significantly in a subset of PWH who had subclinical impairments in CFR at baseline. Moreover, eplerenone may have other novel properties to improve immune function in HIV, aside from its well-known mechanism of action related to BP and sodium regulation.